The genus Myristica is a medicinally important genus belonging to the Myristicaceae. Traditional medicinal systems in Asia have employed plants from the genus Myristica to treat a variety of ailments. Acylphenols and dimeric acylphenols are a rare group of secondary metabolites, which, to date, have only been identified in the Myristicaceae, in particular, in the genus Myristica. The aim of the review would be to provide scientific evidence that the medicinal properties of the genus Myristica could be attributed to the acylphenols and dimeric acylphenols present in the various parts of its plants and highlight the potential in the development of the acylphenols and dimeric acylphenols as pharmaceutical products. SciFinder-n, Web of Science, Scopus, ScienceDirect, and PubMed were used to conduct the literature search between 2013–2022 on the phytochemistry and the pharmacology of acylphenols and dimeric acylphenols from the genus Myristica. The review discusses the distribution of the 25 acylphenols and dimeric acylphenols within the genus Myristica, their extraction, isolation, and characterization from the respective Myristica species, the structural similarities and differences within each group and between the different groups of the acylphenols and dimeric acylphenols, and their in vitro pharmacological activities.
Naegleria fowleri (N. fowleri) is a thermophilic, free-living amoeba that causes primary amoebic meningoencephalitis (PAM), a rapidly fatal brain infection with a mortality rate exceeding 97%. Current treatments are limited and often ineffective, creating an urgent need for new anti-amoebic agents. This study investigates, for the first time, the anti-amoebic potential of malabaricone A-C acylphenol compounds isolated from Myristica cinnamomea (cinnamon nutmeg) against N. fowleri, using both in vitro and in silico approaches. Parasite viability assays were conducted to evaluate the amoebicidal activity of each compound, while cytotoxicity tests on human cell lines assessed their selectivity. Molecular docking studies were performed to predict binding affinities to N. fowleri therapeutic targets, and ADMET profiling evaluated drug-likeness and toxicity. All three malabaricones significantly reduced trophozoite viability, with malabaricone B showing the greatest potency, followed by malabaricone C. Treated amoebae exhibited disrupted membranes, consistent with cell death. Importantly, all compounds displayed low cytotoxicity to mammalian cells at effective concentrations. In silico docking revealed strong binding affinities of the malabaricones, particularly malabaricone B, toward key amoebic proteins involved in metabolism and cell regulation. ADMET predictions indicated favourable pharmacokinetic and safety profiles. This study demonstrates that malabaricone A–C, especially malabaricone B, exhibit potent and selective anti-amoebic activity against N. fowleri, supported by both experimental and computational analyses. These findings position malabaricones as promising natural lead compounds for developing new PAM therapies, addressing a critical unmet need in anti-amoebic drug discovery. By identifying novel natural leads against a neglected yet deadly infection, this study advances Sustainable Development Goal 3 by promoting safer, more effective treatments and addressing health inequities in infectious disease care. Additionally, the integration of in silico methodologies aligns with Sustainable Development Goal 12 by fostering responsible consumption and production through the efficient use of natural resources and the reduction of experimental waste in drug discovery. Graphical Abstract Graphical Overview of in vitro and in silico studies demonstrating the anti-amoebic effects of malabaricone against N. fowleri.